Are you Dr. Freimann?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 70 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
8135 Painter Ave
Suite 103
Whittier, CA 90602Phone+1 562-698-6888Fax+1 562-698-5855
Summary
- Dr. Jack Freimann, MD is an oncologist in Whittier, California. He is currently licensed to practice medicine in California and Texas. He is affiliated with PIH Health Whittier Hospital, Whittier Hospital Medical Center, and Beverly Hospital.
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1988 - 1991
- University of California (Irvine)Residency, Internal Medicine, 1985 - 1988
- David Geffen School of Medicine at UCLAClass of 1985
Certifications & Licensure
- CA State Medical License 1986 - 2025
- TX State Medical License 1989 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
- S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Publications & Presentations
PubMed
- 5 citationsHepatic arterial embolization for treatment of glucagonomas: antineoplastic and palliative benefits.Jack H. Freimann, Richard Pazdur
American Journal of Clinical Oncology. 1990-06-01 - 35 citationsPhase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.Lynn L. Danhauser, Jack H. Freimann, Tracy L. Gilchrist, Jordan U. Gutterman, Carol Y. Hunter
Journal of Clinical Oncology. 1993-04-01